Manish A. Shah, MD

Articles

Dr. Shah on Updated Results With Trastuzumab Deruxtecan in DESTINY-Gastric01

July 23rd 2020

Manish A. Shah, MD, discusses the exciting updated results of the phase 2 DESTINY-Gastric01 study with fam-trastuzumab deruxtecan-nxki in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma.

Dr. Shah on Biomarkers of Response to Immunotherapy in Gastric/GEJ Cancer

May 8th 2020

Manish A. Shah, MD, discusses biomarkers of response to immunotherapy gastric/gastroesophageal cancer.

Dr. Shah on Optimal Sequencing in Gastroesophageal Cancer

April 15th 2020

Manish A. Shah, MD, discusses an optimal sequencing strategy in gastroesophageal cancer.

Dr. Shah on the Role of Immunotherapy in Gastroesophageal Cancer

March 21st 2020

Manish A. Shah, MD, discusses the role of immunotherapy in gastroesophageal cancer.

Dr. Shah on Improving the Benefit of Immunotherapy in Gastric/GEJ Cancer

December 6th 2019

Manish A. Shah, MD, discusses ongoing efforts to improve immunotherapy in gastric and gastroesophageal junction cancer.

Dr. Shah on Biomarkers in Gastric/GEJ Cancer

November 19th 2019

Manish A. Shah, MD, discusses biomarkers in gastric and gastroesophageal junction cancer.

Dr. Shah on the Trastuzumab Biosimilar in Gastric Cancer

October 24th 2019

Manish A. Shah, MD, discusses the use of trastuzumab biosimilars in gastric cancer.

Dr. Shah Discusses the BRIGHTER Study in Gastric Cancer

August 9th 2018

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the BRIGHTER study in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Shah Discusses Challenges With Immunotherapy in Esophageal Cancer

July 31st 2018

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses challenges with immunotherapy in esophageal cancer.

Dr. Shah Highlights Immunotherapy for Esophageal Cancer

July 19th 2018

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, highlights immunotherapy for esophageal cancer.

Dr. Shah on the Relationship Between H. Pylori and Immune Response in Gastric Cancer

April 10th 2018

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the relationship between helicobacter pylori (H. pylori) and immune response in gastric cancer.

Dr. Shah on Risk Factors for Early-Onset CRC

June 8th 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses risk factors for patients with early-onset colorectal cancer (CRC).

Dr. Shah on the Difference in Treatment of Left- and Right-Sided Tumors in CRC

May 2nd 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the difference in treatment of left- and right-sided tumors in colorectal cancer.

Dr. Shah on the Increase of Early-Onset CRC

April 20th 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the increase in prevalence of early-onset colorectal cancer (CRC).

Dr. Shah on Indications of Early-Onset CRC

April 6th 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses indications of early-onset colorectal cancer (CRC).

Dr. Shah on the HELOISE Study for Gastric Cancer

May 20th 2016

Manish A. Shah, MD, associate professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Bartlett Family Associate Professor in Gastrointestinal Oncology, medical oncologist, Weill Cornell Medicine and New-York Presbyterian Hospital, discusses the phase IIIb HELOISE trial, which compared 2 dose regimens of trastuzumab combined with chemotherapy as a first-line treatment for patients with HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma (mGC/GEJC).

Dr. Manish Shah on the METGastric Study

June 4th 2015

Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

Dr. Manish Shah on MET Inhibitors Not Improving PFS in MET-Positive GEC

April 17th 2015

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medical College/New York Presbyterian Hospital, discusses why MET inhibitors such as onartuzumab do not improve progression-free survival for the treatment of metastatic, HER2-negative gastroesophageal adenocarcinoma.

Dr. Manish Shah on Onartuzumab for Gastroesophageal Adenocarcinoma

January 16th 2015

Manish A. Shah, MD, talks about a recent phase II study of mFOLFOX paired with the MET inhibitor onartuzumab for the treatment of metastatic, HER2-negative gastroesophageal adenocarcinoma (GEC).